Pharmacokinetics of oral ciprofloxacin in adult patients: A scoping review

• Published in: British journal of clinical pharmacology Vol. 90; no. 2; pp. 528 - 547
• Main Authors: Junkert, Allan Michael, Lazo, Raul Edison Luna, Deffert, Flávia, Carneiro, Jaqueline, Borba, Helena Hiemisch Lobo, Campos, Michel Leandro, Pontarolo, Roberto
• Format: Journal Article
• Language: English
• Published: England 01.02.2024
• Subjects: Adult; Aged; Ciprofloxacin; Humans; pharmacokinetics; PK/PD; popPK; Renal Replacement Therapy; scoping review; pharmacokinetics; PK/PD; popPK; ciprofloxacin; scoping review
• ISSN: 0306-5251; 1365-2125; 1365-2125
• DOI: 10.1111/bcp.15933

Aims To map the literature on oral ciprofloxacin's pharmacokinetics and its implications for dose adjustments in specific populations. Methods A scoping review was performed according to the Cochrane Collaboration and JBI and reported following the PRISMA‐ScR. Systematic searches on electronic databases were conducted to integrate the current evidence on ciprofloxacin's pharmacokinetics. The quality of the included studies was assessed using ClinPK's checklist. Results The search yielded 55 relevant studies. Within the traditional pharmacokinetics studies (n = 46), 86 profiles were examined (72 involving healthy patients and 14 with various clinical conditions). Oral ciprofloxacin's pharmacokinetics were influenced by covariates such as drug interactions (ferrous ions, calcium carbonate, diclofenac and itraconazole), food interactions (calcium‐rich foods), elderly populations and renal impairment. Notably, variability in pharmacokinetic parameters existed among subjects, regardless of their health status, underscoring the need for comprehensive population descriptions. Population pharmacokinetic studies (n = 9) identified significant covariates for hospitalized patients, such as creatinine clearance, plasma bicarbonate, estimated glomerular filtration rate, renal replacement therapy, age, sex, total bilirubin, fat‐free mass, dietary factors in renal disease, rifampicin for clearance models and body weight for volume of distribution models. Most pharmacokinetic/pharmacodynamic assessments concluded that 1200 mg/day provides a high probability of target attainment for bacteria with minimum inhibitory concentration <0.5 mg L−1, aiming for an area under the curve for 24 h/minimum inhibitory concentration >125 h. Conclusions This study offers a comprehensive overview regarding oral ciprofloxacin's pharmacokinetics across various health conditions. It highlights the complexities of ciprofloxacin's pharmacokinetics, emphasizing the importance of considering multiple factors in dose adjustments.